Berliner Boersenzeitung - Once-taboo ketamine booms for US at-home mental care

EUR -
AED 4.306153
AFN 75.0429
ALL 95.503739
AMD 434.75432
ANG 2.098709
AOA 1076.390828
ARS 1633.24778
AUD 1.628526
AWG 2.110569
AZN 1.997971
BAM 1.957785
BBD 2.362126
BDT 143.899979
BGN 1.955914
BHD 0.44281
BIF 3489.474751
BMD 1.172539
BND 1.496038
BOB 8.103802
BRL 5.808644
BSD 1.172804
BTN 111.252582
BWP 15.938311
BYN 3.309523
BYR 22981.755751
BZD 2.358712
CAD 1.59436
CDF 2720.28988
CHF 0.91605
CLF 0.026783
CLP 1054.112588
CNY 8.006387
CNH 8.009617
COP 4288.442525
CRC 533.195048
CUC 1.172539
CUP 31.072272
CVE 110.746729
CZK 24.373212
DJF 208.384014
DKK 7.475055
DOP 69.770598
DZD 155.365983
EGP 62.894658
ERN 17.588078
ETB 184.088973
FJD 2.570327
FKP 0.860939
GBP 0.862002
GEL 3.142861
GGP 0.860939
GHS 13.136953
GIP 0.860939
GMD 85.595732
GNF 10289.026269
GTQ 8.959961
GYD 245.356495
HKD 9.186899
HNL 31.213432
HRK 7.537125
HTG 153.631453
HUF 363.42071
IDR 20325.193765
ILS 3.451755
IMP 0.860939
INR 111.286226
IQD 1536.025512
IRR 1540715.666567
ISK 143.847483
JEP 0.860939
JMD 183.766277
JOD 0.831376
JPY 184.174195
KES 151.433806
KGS 102.503912
KHR 4704.815418
KMF 492.466605
KPW 1055.342165
KRW 1725.179882
KWD 0.36031
KYD 0.977362
KZT 543.223189
LAK 25772.39793
LBP 105000.828342
LKR 374.82671
LRD 215.600573
LSL 19.53494
LTL 3.462202
LVL 0.709257
LYD 7.446066
MAD 10.847448
MDL 20.206948
MGA 4866.035425
MKD 61.633886
MMK 2461.86164
MNT 4196.707877
MOP 9.463379
MRU 46.86681
MUR 55.144932
MVR 18.121629
MWK 2041.980281
MXN 20.469245
MYR 4.655421
MZN 74.929587
NAD 19.534934
NGN 1613.390048
NIO 43.044332
NOK 10.900392
NPR 177.995572
NZD 1.986849
OMR 0.451129
PAB 1.172774
PEN 4.112684
PGK 5.087352
PHP 71.847345
PKR 326.874482
PLN 4.245704
PYG 7213.019006
QAR 4.272149
RON 5.203848
RSD 117.378833
RUB 87.908248
RWF 1713.665104
SAR 4.396996
SBD 9.429684
SCR 16.118093
SDG 704.113715
SEK 10.803423
SGD 1.492177
SHP 0.875418
SLE 28.848748
SLL 24587.542811
SOS 669.519913
SRD 43.920994
STD 24269.180819
STN 24.869543
SVC 10.262409
SYP 129.594933
SZL 19.534925
THB 38.122791
TJS 11.000548
TMT 4.109748
TND 3.378963
TOP 2.823192
TRY 52.931326
TTD 7.960816
TWD 37.086813
TZS 3054.463338
UAH 51.532291
UGX 4409.902668
USD 1.172539
UYU 46.771998
UZS 14011.836168
VES 573.304233
VND 30903.426254
VUV 139.40416
WST 3.183663
XAF 656.670246
XAG 0.01556
XAU 0.000254
XCD 3.168845
XCG 2.113677
XDR 0.815653
XOF 656.621982
XPF 119.331742
YER 279.771908
ZAR 19.540971
ZMK 10554.258277
ZMW 21.901789
ZWL 377.556938
  • BCE

    0.1800

    23.96

    +0.75%

  • CMSD

    0.1500

    23.28

    +0.64%

  • GSK

    -0.7000

    51.61

    -1.36%

  • RBGPF

    0.5000

    63.1

    +0.79%

  • BP

    -0.9700

    46.41

    -2.09%

  • RIO

    0.1000

    100.58

    +0.1%

  • JRI

    -0.0100

    12.98

    -0.08%

  • AZN

    -2.6300

    184.74

    -1.42%

  • BTI

    -0.0900

    58.71

    -0.15%

  • NGG

    -1.0600

    88.48

    -1.2%

  • RYCEF

    0.5500

    16.35

    +3.36%

  • BCC

    -1.1400

    78.13

    -1.46%

  • RELX

    -0.2400

    36.35

    -0.66%

  • VOD

    0.3500

    16.15

    +2.17%

  • CMSC

    0.0600

    22.88

    +0.26%

Once-taboo ketamine booms for US at-home mental care
Once-taboo ketamine booms for US at-home mental care

Once-taboo ketamine booms for US at-home mental care

Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.

Text size:

A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.

Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.

"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."

Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.

It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.

In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.

- Ketamine 'babysitter' -

Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.

An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.

Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.

"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.

For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.

Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.

"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.

Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.

- 'Change your life' -

US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.

Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.

He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.

"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.

Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.

Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.

Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.

"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.

(B.Hartmann--BBZ)